179 related articles for article (PubMed ID: 29453321)
1. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
3. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.
Tuettenberg J; Seiz M; Debatin KM; Hollburg W; von Staden M; Thiemann M; Hareng B; Fricke H; Kunz C
Int Immunopharmacol; 2012 May; 13(1):93-100. PubMed ID: 22446296
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
6. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.
Hartmann N; Messmann JJ; Leithäuser F; Weiswange M; Kluge M; Fricke H; Debatin KM; Strauss G
Blood; 2013 Jan; 121(3):556-65. PubMed ID: 23203823
[TBL] [Abstract][Full Text] [Related]
7. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
8. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.
Krendyukov A; Gieffers C
Cancer Manag Res; 2019; 11():8095-8100. PubMed ID: 31564969
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
10. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
11. Yes and PI3K bind CD95 to signal invasion of glioblastoma.
Kleber S; Sancho-Martinez I; Wiestler B; Beisel A; Gieffers C; Hill O; Thiemann M; Mueller W; Sykora J; Kuhn A; Schreglmann N; Letellier E; Zuliani C; Klussmann S; Teodorczyk M; Gröne HJ; Ganten TM; Sültmann H; Tüttenberg J; von Deimling A; Regnier-Vigouroux A; Herold-Mende C; Martin-Villalba A
Cancer Cell; 2008 Mar; 13(3):235-48. PubMed ID: 18328427
[TBL] [Abstract][Full Text] [Related]
12. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
13. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.
Eisele G; Roth P; Hasenbach K; Aulwurm S; Wolpert F; Tabatabai G; Wick W; Weller M
Neuro Oncol; 2011 Feb; 13(2):155-64. PubMed ID: 21183510
[TBL] [Abstract][Full Text] [Related]
14. CD95 signaling in cancer treatment.
De la Rosa AJ; Gomez MA; Morales S; Padillo FJ; Muntane J
Curr Pharm Des; 2014; 20(17):2809-18. PubMed ID: 23944368
[TBL] [Abstract][Full Text] [Related]
15. CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner.
Quijano-Rubio C; Silginer M; Weller M
Cell Death Discov; 2022 Jul; 8(1):341. PubMed ID: 35906203
[TBL] [Abstract][Full Text] [Related]
16. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H
J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474
[TBL] [Abstract][Full Text] [Related]
17. The dual role of the CD95 and CD95L signaling pathway in glioblastoma.
Zhang Y; Jin T; Dou Z; Wei B; Zhang B; Sun C
Front Immunol; 2022; 13():1029737. PubMed ID: 36505426
[TBL] [Abstract][Full Text] [Related]
18. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
19. Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions.
Streffer JR; Schuster M; Pohl U; Belka C; Dichgans J; Bamberg M; Weller M
Anticancer Res; 1999; 19(6B):5265-9. PubMed ID: 10697547
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]